Spirovant Sciences
PA - PhiladelphiaBiotechnology
Focus: Gene Therapy - Lung Diseases
Spirovant Sciences is a life sciences company focused on Gene Therapy - Lung Diseases.
Profile data last refreshed Yesterday
Funding Stage
PUBLIC
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SP-101 and doxorubicin Cohort 1
Cystic FibrosisClinical Trials (1)
NCT06526923A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Phase 1/2Help build intelligence for Spirovant Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.